Prophylactic Effects of Ondansetron, Ramosetron, and Palonosetron on Patient-Controlled Analgesia Related Nausea and Vomiting After Urologic Laparoscopic Surgery

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01169805

Enrollment

105

Registered

2010-07-26

Start date

2010-08-31

Completion date

2011-06-30

Last updated

2011-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic Marsupialization of Renal Cyst

Brief summary

The aim of this prospective randomized controlled study was to compare the prophylactic effects of intravenous single dose of ondansetron, ramosetron, and palonosetron on PCA-related nausea and vomiting after urologic laparoscopic surgery.

Interventions

DRUGOndansetron

Ondansetron/single injection/4 mg/IV

DRUGRamosetron

Ramosetron HCl/single injection/0.3mg/IV

DRUGPalonosetron

Palonosetron HCl/single injection/0.075mg/IV

DRUGNormal saline inj

normal saline injection 2ml

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

DOUBLE (Caregiver, Investigator)

Eligibility

Sex/Gender

FEMALE

Age

20 Years to 65 Years

Healthy volunteers

Inclusion criteria

* ASA I or II * Patients aged (20-65 yr) Undergoing Laparoscopic Nephrectomy * Patients who want a patient-controlled IV analgesia (IV-PCA)

Exclusion criteria

* History of allergy or hypersensitivity to 5-HT3 antagonist * History of severe postoperative nausea/vomiting * Prolonged QT interval on preoperative EKG * Hypokalemia, Hypomagnesemia * Intestinal obstruction * Pregnant female or breast feeding mother

Design outcomes

Primary

Measure	Time frame
severity of nausea	during 73 hours after surgery
the number of vomiting	during 73 hours after surgery

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026